Anti Tuberculosis Therapeutics Market Report and Forecast 2024-2032

Anti Tuberculosis Therapeutics Market Outlook

The anti tuberculosis therapeutics market size was valued at USD 1354 million in 2023, driven by the increasing incidence of tuberculosis and the rising number of studies around tuberculosis therapeutics. The market size is anticipated to grow at a CAGR of 7.6% during the forecast period of 2024-2032 to achieve a value of USD 2589.8 million by 2032.

Anti Tuberculosis Therapeutics Market Overview

Tuberculosis (TB) is caused by mycobacterium tuberculosis. Tuberculosis treatment involves a combination of antibiotics which are recommended by the healthcare professionals to the patients. These antibiotics are taken over several months to ensure the complete removal of the bacteria and prevent the development of drug-resistant strains of the disease. The standard regimen for tuberculosis treatment often includes multiple drugs to target different aspects of the infection and prevent the bacteria from becoming resistant to treatment. Some key medications used in anti-tuberculosis therapy include Isoniazid (INH), Rifampin (RIF), Pyrazinamide (PZA), ethambutol, streptomycin and other aminoglycosides, fluoroquinolones.

The anti tuberculosis therapeutics market growth is expected to grow significantly during the forecast period owing to several pivotal factors including the escalating prevalence of tuberculosis worldwide, with a stressful rise in multi-drug resistant (MDR) and extensively drug-resistant (XDR) cases in developing nations. This surge in incidences is fostering increased demand for anti-tuberculosis medications in the forecast period, propelling the market growth. Furthermore, the market growth is driven by the proactive measures by government and private organizations to spread awareness about tuberculosis.

Research and Development to Aid the Market Growth

The market is expected to witness significant growth in the forecast period, driven by key developments and ongoing research initiatives. For instance, the SimpliciTB trial's evaluation of the BPaMZ regimen has recently exhibited promising efficacy and treatment-shortening potential, elevating optimism and hope for effective tuberculosis management among patients and their families. Such trials are expected to drive the anti tuberculosis therapeutics market growth in the forecast period.

Isoniazid as a Potential Treatment for Alzheimer's Disease

Furthermore, the market growth is anticipated to be driven by the exploration of Isoniazid as a potential treatment for Alzheimer's disease presents a dual opportunity, that includes expanded therapeutic applications beyond TB treatment. Such observational research may lead to more experiments and observational studies in the market to explore the full potential of other drugs in the treatment of TB, resulting in widespread application opportunities, and bolstering the market growth.

Rising Efforts by Researchers to Drive the Growth

Additionally, a recent modeling study discussing the introduction of a new TB vaccine in low or middle-income countries (LMICs), concluded that it will promise substantial health and economic benefits to the anti tuberculosis therapeutics market in the countries.  These modeling studies by researchers may pull the traction of pharmaceutical and biotechnology companies to understand the urgency of the situation and create opportunities for them to fill a crucial gap in the market, likely to contribute to the anti tuberculosis therapeutics market share during the forecast period.

Clinical Trials to Drive Significant Development

In November 2023, TB Alliance launched a new Pan-Phase 2 clinical trial incorporating elements of Phase 2a, b, and c, identified as NC-009, to evaluate the safety and efficacy of a combination of a new experimental compound, TBAJ-876, with pretomanid and linezolid, components of TB Alliance’s BPaL regimen. This regimen has the potential to shorten and improve treatment for both drug-sensitive and drug-resistant tuberculosis (TB), one of the world’s deadliest infectious diseases. Results from preclinical and Phase 1 studies presented at the Union Conference showed that the new compound when compared with bedaquiline (a TB medicine in the same drug class), eliminated TB bacteria faster and had a potentially safer profile.

Such clinical trials are expected to drive the anti tuberculosis therapeutics market growth by enabling healthcare professionals to pay attention to the formulation of the TB drugs that they are prescribing to TB patients. However, this approach is also expected to provide convenience as exhibited by the results, with chances of non-compliance while improving success rates of the treatment, boosting the market growth.

Anti Tuberculosis Therapeutics Market Segmentations

Market Breakup by Treatment Type

• First-Line of Drugs

• Second-Line of Drugs

• Others

Market Breakup by Disease Type

• Active TB

• Latent TB 

• Others

Market Breakup by Diagnosis

• Blood Tests

• Imaging Tests

• Sputum Tests

• Others

Market Breakup by Route of Administration

• Oral

• Parenteral

• Others

Market Breakup by Dosage Form

• Tablets

• Capsules

• Injections

• Others

Market Breakup by End User

• Hospitals

• Specialty Clinics

• Others

Market Breakup by -7MM

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Anti Tuberculosis Therapeutics Market Regional Analysis

The United States has been leading the market and is likely to continue leading the market in the forecast period as well. For instance, in September 2023, the United States, through USAID, announced more than USD 23 million, as well as new efforts to support countries in fighting tuberculosis (TB) and reaching global targets set at a meeting during United Nations High Level Week. Working with Congress, the new efforts that are part of USAID’s Global Accelerator to End TB Plus package are part of more than USD 394 million in planned FY 2023 investments and illustrate USAID's steadfast commitment to ending TB globally.  Such funding activities play a crucial role in incentivizing research and deelopment in pharmaceutical companies to develop innovative therapies, drugs, and treatment modalities for TB. Such funding may also support manufacturing and the widespread distribution of drugs to fulfill a crucial gap of unmet medical needs in this domain, likely to aid the anti tuberculosis therapeutics market size in the forecast period.

Geographically, the Middle East and African regions are expected to lead the market growth in the forecast period. The presence of a huge patient pool and the unavailability of effective treatments are expected to provide opportunities for pharmaceutical companies and other organizations to fill a crucial gap in the market. The incidence is also expected to increase in countries that are developing with small incomes.

Anti Tuberculosis Therapeutics Market: Competitor Landscape

In September 2023, Global health aid agency Unitaid wrote to Johnson & Johnson's (JNJ.N) CEO, Joaquin Duato, urging "immediate action" to expand access to the company's tuberculosis drug bedaquiline, which is protected by patents hindering generic alternatives. While J&J has lowered the price of bedaquiline, which is used to treat drug-resistant tuberculosis (DR-TB), Unitaid said it was an "incomplete solution" and countries like South Africa, Belarus, and Ukraine were not benefiting.

The key features of the anti tuberculosis therapeutics market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• AstraZeneca

• Johnson & Johnson Private Limited 

• Eli Lilly and Company 

• F. Hoffmann-La Roche Ltd.  

• Mylan N.V. 

• Teva Pharmaceutical Industries Ltd. 

• Sanofi 

• Novartis 

• Allergan 

• Merck & Co.  

• STI Pharma 

• Endo International plc  

• Fresenius Kabi AG 

• Hikma Pharmaceuticals PLC

Please note that this only represents a partial' list of companies, and the complete list has been provided in the report.

Key Highlights of the Report